Target intelligence / Profile preview

Cell proliferation pathways in 3T3-L1 preadipocytes

Molecular classification
Other
01

Overview

Cell proliferation pathways in 3T3-L1 preadipocytes refer to the integrated network of signaling cascades that control the growth and division of mouse embryonic fibroblast-like cells prior to their conversion into mature fat cells (Green & Kehinde, 1974, Cell). A defining feature of this process is mitotic clonal expansion (MCE), a mandatory phase where arrested preadipocytes re-enter the cell cycle and undergo several rounds of division in response to adipogenic stimuli (Tang et al., 2003, PNAS). These pathways are primarily driven by the Mitogen-Activated Protein Kinase (MAPK/ERK) and Phosphoinositide 3-kinase (PI3K/Akt) systems, which are activated by hormones such as insulin and insulin-like growth factor 1 (Sakaue et al., 1998, JBC). Understanding these proliferative pathways is critical in metabolic research because the number of adipocytes in an individual is largely determined by the proliferation of precursor cells, a process that contributes significantly to the development of hyperplastic obesity (Sarjeant & Stephens, 2012, Critical Reviews in Clinical Laboratory Sciences). Pharmacological agents often target these pathways to either inhibit excessive fat tissue expansion or to study the molecular mechanisms of insulin resistance. While not a single molecular target, this biological context serves as a fundamental model for screening compounds that modulate adipogenesis and energy homeostasis (PubMed, NIH).

Other names
3T3-L1 Mitotic clonal expansionPreadipocyte proliferation signalingAdipocyte precursor cell cycle pathways
02

Mechanism of action

Activation or inhibition of intracellular signaling cascades, primarily the MAPK/ERK and PI3K/Akt pathways, to regulate the entry of preadipocytes into the cell cycle and subsequent mitotic clonal expansion.

03

Biological functions

Cell proliferationSignal transductionCell cycleAdipogenesis
04

Disease associations

ObesityMetabolic syndromeDiabetes mellitus
05

Safety considerations

Systemic off-target effects on non-adipose cell proliferationPotential for oncogenesis if growth pathways are constitutively activatedMetabolic dysregulation resulting from altered adipocyte hyperplasia
06

Interacting drugs

Insulin

4 more in the full profile.

07

Biomarkers

Cyclin D1Proliferating cell nuclear antigen (PCNA)Phospho-ERK1/2Phospho-AktKi-67

Beyond the preview

Go deeper on Cell proliferation pathways in 3T3-L1 preadipocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell proliferation pathways in 3T3-L1 preadipocytes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call